Calcium channel blocker amlodipine besylate is associated with reduced case fatality rate of COVID-19 patients with hypertension

CCBs inhibit SARS-CoV-2 infection in vitro

To test whether CCBs can inhibit SARS-CoV-2 replication, Vero E6 cells were treated with a panel of 9 clinically approved CCBs, and then infected with SARS-CoV-2 at a multiplicity of infection (MOI) of 0.05. At 24 hours post infection (p.i.), copy numbers of viral RNA in the supernatant were measured with qRT-PCR (Figure 1A), and the intracellular level of virus infection was monitored by immunofluorescence with an antibody against virus NP protein (Figure 1B). We found that four CCBs, benidipine HCI, amlodipine besylate, cilnidipine and nicardipine HCI, significantly inhibited SARS-CoV-2 replication (Figure 1). Experiments with serial concentrations of drug treatment revealed that these four CCBs inhibited SARS-CoV-2 replication in a dose-dependent manner, without causing strong cytotoxic effect (Figure 2A). The half maximal inhibitory concentrations (IC₅₀) of benidipine HCI, amlodipine besylate, cilnidipine, nicardipine HCI were 3.81, 4.17, 11.58 and 13.32 μM, respectively, and the half cytotoxic concentration (CC₅₀) of all four drugs were calculated to be above 100 μM. The drug selection index (SI) of these four CCBs was calculated to be > 26.25, > 23.98, >8.64 and >7.51, respectively (Figure 2A). Similar inhibition effects of these four CCBs were also observed on the human hepatocyte cell line Huh7 (Supplementary Figure S1).

• Download figure
• Open in new tab

Figure 1. Evaluation of anti-SARS-CoV-2 activity of a panel of CCBs.

Vero E6 cells were treated with indicated concentrations of compounds and infected with SARS-CoV-2 at an MOI of 0.05, and at 24 hours p.i., supernatant was collected and cells were fixed. Chloroquine (CQ, 5 μM) was used as positive control. (A) Viral copy number in the supernatant was measured with quantitative RT-PCR; (B) intracellular NP level in cells treated with 30 μM indicated compound was monitored with immunofluorescence. The experiments were done in triplicates, and data shown are means ± SD. Bars: 400 μm.

• Download figure
• Open in new tab

Figure 2. Dose dependent effects of benidipine HCI, amlodipine besylate, cilnidipine, nicardipine HCl, BAPTA-AM and 2ABP on SARS-CoV-2 replication.

Vero E6 cells were treated with indicated concentrations of compounds and infected with SARS-CoV-2 at an MOI of 0.05, and at 24 hours p.i., supernatant was collected and viral copy number in the supernatant was measured with quantitative RT-PCR. Cell viability was measured with CCK8 assay. The left Y-axis of the graph indicates mean % inhibition of virus, while right Y-axis represents mean % cell viability. The experiments were done in triplicates, and data shown are means ± SD. The IC₅₀ and CC₅₀ values were calculated by Graphpad Prism 6.0.

Since CCBs block intracellular calcium influx, we analyzed whether the anti-SARS-CoV-2 effect of CCBs is related with reduced intracellular calcium level. Intracellular calcium level can be reduced through treatment with calcium chelator 1,2-Bis(2-aminophenoxy)ethane-N,N,N’,N’-tetraacetic acid tetrakis(acetoxymethyl ester) (BAPTA-AM) or 2-Aminoethyl Diphenylborinate (2APB), a membrane permeable blocker of the inositol 1,4,5-trisphosphate (IP3)-induced Ca²⁺ release (17). Vero E6 cells were treated with serial concentrations of BAPTA-AM or 2APB, and then infected with SARS-CoV-2. At 24 hours p.i., copy numbers of viral RNA in the supernatant were measured with qRT-PCR. As shown in figure 2B, addition of BAPTA-AM or 2APB also significantly inhibited virus replication in a concentration dependent manner, confirming the dependence role of intracellular Ca²⁺ for SARS-CoV-2 replication.

CCB inhibits viral replication at the post-entry stage

To define the event of virus infection that was inhibited by CCBs, time-of-addition assay of drug treatment was performed. The CCB benidipine HCI was chosen for further analysis as it has the lowest effective concentration and the highest SI index of the 4 tested CCBs. Benidipine HCI or 2ABP were added during virus entry, 2-hours post virus infection or through-out virus infection (Figure 3A). The virus production in the supernatant was measured with qRT-PCR and the intracellular NP expression level was determined with western blot and immunofluorescence analysis with the NP antibody. As shown in figure 3B-D, addition of drug through-out virus infection or 2-hours after virus entry strongly inhibited virus production, while addition of drug during virus entry did not inhibit virus replication. Notably, compared with drug treatment throughout virus infection, addition of drugs 2-hours after virus entry had slightly lower inhibition efficacy (Figure 3 B,C). Whether this is due to rapid onset of virus replication within the first 2-hours that was not fully blocked by following drug treatment still needs further characterization. Nevertheless, these results indicate that benidipine HCI and 2ABP mainly inhibit virus infection at a stage after virus entry, potentially during virus genome replication/transcription.

• Download figure
• Open in new tab

Figure 3. Time-of-addition experiment of benidipine HCI and 2ABP.

(A) For “Full-time” treatment, Vero E6 cells were pre-treated with compounds for 1 hour, and then infected with virus. At 2 hours p.i., the supernatant was removed, and the cells were cultured with compound-containing medium until the end of the experiment. For “Entry” treatment, Vero E6 cells were pre-treated with compounds for 1 hour, and then infected with virus. At 2 hours p.i., the supernatant was removed, and the cells were cultured with fresh culture medium until the end of the experiment. For “Post-entry” experiment, Vero E6 cells were infected with virus, and at 2 hours p.i., cells were treated with compound-containing medium until the end of the experiment. For all these experiments, Vero E6 cells were infected with SARS-CoV-2 at an MOI of 0.05, and virus copy number in the supernatant was quantified by quantitative RT-PCR (B) and NP expression in infected cells was analyzed by western blot (C) and immunofluorescence with NP antibody (D) at 24 hours p.i.. The Y-axis of the graph represents mean % inhibition of virus. The experiments were performed in triplicates.

CCBs but not ARBs or ACEIs display inhibitory effect against SARS-CoV-2 replication

Angiotensin II receptor blockers (ARB), angiotensin converting enzyme inhibitors (ACEI) and CCBs represent three major types of anti-hypertension drugs that are in clinical use (18). We next analyzed whether the ARB and ACEI anti-hypertension drugs can also inhibit SARS-CoV-2 replication. Representative ARBs (losartan potassium, valsartan) or ACEIs (enalaprilat dihydrate, enalapril maleate) that are widely used in the clinics (18) were chosen for the evaluation of potential anti-viral effect. Vero E6 cells were treated with serial concentrations of drug compounds and infected with SARS-CoV-2 at an MOI of 0.05. At 24 hours p.i., viral copy number in the supernatant was measured with qRT-PCR and cell viability was measured with CCK-8 assay. As shown in figure 4, in contrast to the distinct inhibition efficacy against SARS-CoV-2 of CCBs, the selected ARBs or ACEIs did not show any significant inhibition effect. These results suggested that of the three types of anti-hypertension drugs only CCBs have significant anti-SARS-CoV-2 efficacy.

• Download figure
• Open in new tab

Figure 4. Effect of drug treatment with two ACEIs (enalaprilat dihydrate, enalapril maleate) or two ARBs (losartan potassium, valsartan) on SARS-CoV-2 replication in vitro.

Vero E6 cells were treated with indicated concentrations of compounds and infected with SARS-CoV-2 at an MOI of 0.05. At 24 hours p.i., supernatant was collected and viral copy number in the supernatant was measured with quantitative RT-PCR. Cell viability was measured with CCK8 assay. The left Y-axis of the graph indicates mean % inhibition of virus, while right Y-axis represents mean % cell viability. The experiments were performed in triplicates, and data shown are means ± SD.

Combined application of chloroquine (CQ) with CCB resulted in enhanced anti-SARS-CoV-2 effect

CQ was recently reported to inhibit the entry stage of SARS-CoV-2 replication (5). Considering that CCB may inhibit SARS-CoV-2 at the post-entry stage, we analyzed whether the combined application of CQ and CCB would lead to a more distinct inhibition effect. CQ and CCB were added separately or in combination to the Vero E6 cells followed by virus infection with SARS-CoV-2 at the MOI of 0.05. At 24 hours p.i., copy numbers of viral RNA in the supernatant were measured with qRT-PCR and the intracellular level of virus infection was monitored by immunofluorescence with the NP antibody. As shown in figure 5, while separate application of CQ or benidipine HCI resulted in distinct reduction of virus replication, the combined application of benidipine HCI and CQ further enhanced the anti-SARS-CoV-2 efficacy (P < 0.001).

• Download figure
• Open in new tab

Figure 5. The antiviral activities of chloroquine (CQ) and/or benidipine HCI against SARS-CoV-2 replication.

Vero E6 cells were treated with indicated concentrations of compounds separately or in combination and infected with SARS-CoV-2 at an MOI of 0.05. At 24 hours p.i., supernatant was collected and viral copy number in the supernatant was measured with quantitative RT-PCR (A), and NP expression in infected cells was analyzed by immunofluorescence with NP antibody (B). The experiments were performed in triplicates, and data shown are means ± SD. Comparison of mean values between two groups was analyzed by the student’s t test. *p < 0.05; **p < 0.01; ***p < 0.001. Bars: 400 μm.

Administration of amlodipine besylate is associated with reduced case fatality rate in COVID-19 patients with hypertension

In order to evaluate whether CCBs have therapeutic effect in COVID-19 patients, we retrospectively analyzed the medical record of 487 adult COVID-19 patients with hypertension, including 225 had been admitted into the Tongji Hospital from January 17 to February 14,, and 262 had been admitted into the Union Hospital from January 10 to March 30, 2020. Of these patients 331 concurrently had other underlying comorbidities such as diabetes, chronic obstructive pulmonary disease, cerebral infarction, etc, 56 had no information on antihypertensive treatment, and 10 were still in the hospital. The 90 patients, who only had hypertension as the comorbidity and were either discharged from the hospital or deceased, were included for the retrospective analysis. Among these patients 44 received amlodipine besylate, 16 received nifedipine, 4 received other CCBs, 17 received other antihypertensive drugs (including ARBs, ACEIs, β-blockers, and thiazide), and 9 had no anti-hypertension drug treatment. No patient was found receiving benidipine HCI treatment. All the patients who did not receive amlodipine besylate were defined as non-amlodipine besylate treated patients. For amlodipine besylate treated and non-amlodipine besylate treated patients, the median (IQR) age was 67 (59.5-72) and 65 (57-74) years, and the median (IQR) delay from symptom onset to hospital admission was 10 (7-14) and 8.5 (6-13.5) days, respectively. Both of the two variables showed no significant inter-group difference. The female proportion was lower in amlodipine besylate treated patients (37.0%) than that (59.1%) in non-amlodipine besylat treated patients, (P = 0.036, Supplementary information, Table S1). The frequencies of clinical manifestations that were recorded before or at admission, including fever, cough, feeble, chest distress, shortness of breath, and gastrointestinal symptoms, were comparable between the two groups (all P > 0.05, Supplementary information, Table S1). Compared to the non-amlodipine besylate treated group, the amlodipine besylate treated group had lower serum levels of total bilirubin and lactate dehydrogenase (P = 0.047 and P = 0.015, respectively; Supplementary information, Table S1). All other laboratory parameters tested at admission were comparable. The commonly prescribed therapies during hospitalization included antibiotics, antiviral agents, traditional Chinese medicines, corticosteroids, and respiratory support. The amlodipine besylate treated group had lower frequency of antibiotics and higher frequency of corticosteroids (P = 0.028 and P = 0.006, respectively; Supplementary information, Table S2), while other therapies were observed with comparable frequencies between the two groups.

For the primary outcome of mortality, a beneficial effect in reducing the case fatality rate (CFR) was observed in patients receiving amlodipine besylate, with the CFR being significantly decreased from 26.1% (12/46) in non-amlodipine besylate treated group to 6.8% (3/44) in amlodipine besylate treated group (P = 0.022). Kaplan-Meier analysis similarly demonstrated reduced risk of death in amlodipine besylate treated group, in comparison with non-amlodipine besylate treated group (P = 0.033, log-rank test; Figure 6A). The effect amlodipine besylate treatment of on CFR remained significant with the use of Cox regression model by adjusting for age, sex, the delay from symptom onset to hospital admission, and therapies administration (hazard ratio (HR) 0.182, 95% confidence interval (CI) 0.037-0.897, P = 0.036; Table 1). Further analysis showed that the CFRs were higher in all other patient groups, with 12.5% (2/16) in patients receiving nifedipine, 25.0 (1/4) in patients receiving other CCBs, 41.2% (7/17) in patients receiving other anti-hypertension drugs, 22.2% (2/9) in patients without receiving anti-hypertension drugs. When compared to the patients without receiving anti-hypertension drugs, significant treatment effect was only observed in the patients receiving amlodipine besylate (Table 1; Figure 6B).

• Download figure
• Open in new tab

Figure 6. Analysis of amlodipine besylate treatment on probability of survival in COVID-19 patients with hypertension.

Treatment effect on probability of survival of amlodipine besylate treated patients was compared with non-amlodipine besylate treated patients (A), or with patients received different types of anti-hypertension drugs (B). Other antihypertensive drugs include angiotensin receptor blockers, angiotensin converting enzyme inhibitors, β-blockers, and thiazide. The Kaplan-Meier method was used to analyze the time-to-event data.

Cells, virus and reagents

Vero E6 cell line was obtained from American Type Culture Collection (ATCC) and maintained in minimum Eagle’s medium (MEM; Gibco Invitrogen) supplemented with 10% fetal bovine serum (FBS; Gibco Invitrogen), 1% antibiotic/antimycotic (Gibco Invitrogen), at 37 °C in a humidified 5% CO₂ incubator. Huh7 cell line was cultured in Dulbecco’s modified Eagle’s medium (DMEM; Gibco Invitrogen) supplemented with 10% FBS, 1% antibiotic/antimycotic (Gibco Invitrogen), at 37 °C in a humidified 5% CO₂ incubator.

SARS-CoV-2 (nCoV-2019BetaCoV/Wuhan/WIV04/2019) was propagated in Vero E6 cells (2), and viral titer was determined by 50% tissue culture infective dose (TCID50) as described in our previous study(5). All the infection experiments were performed in a biosafety level-3 (BLS-3) laboratory.

Benidipine HCI (Selleck Chemicals, no. S2017), Amlodipine besylate (Selleck Chemicals, S1813), Cilnidipine (Selleck Chemicals, S1293), Nicardipine HCl (Selleck Chemicals, S4181), Nifedipine (Selleck Chemicals, S1808), Isradipine (Selleck Chemicals, S1662), Nimodipine (Selleck Chemicals, S1747), Nisoldipine (Selleck Chemicals, S1748), Felodipine (Selleck Chemicals, S1885), 2-Aminoethyl Diphenylborinate (2APB, Selleck Chemicals, S6657), BAPTA-AM (Selleck Chemicals, S7534) and Chloroquine (Sigma-Aldrich, no.C6628) were purchased from indicated companies.

Evaluation of the antiviral activities of the test compounds

Vero E6 pre-seeded in 48-well dish (1 × 10⁵ cells/well) were treated with the different concentration of the indicated compounds for 1 hour and infected with SARS-CoV-2 at an MOI of 0.05. Two hours later, the virus-drug mixture was removed and cells were cultured with drug containing medium. At 24 hours p.i., the cell supernatant was collected and lysed. The viral RNA extraction and quantitative real time PCR (RT-PCR) analysis was described in our previous study (5).

Evaluation of the cytotoxicity of the test compounds

Vero E6 pre-seeded in 96-well dish (5 × 10⁴ cells/well) were treated with the different concentration of the indicated compounds, and 24 hours later, the relative numbers of surviving cells were measured with cell counting kit-8 (GK10001,GLPBIO) according to the manufacturer’s instructions.

Immunofluorescence microscopy

To detect intracellular expression level of viral NP, cells were fixed with 4% paraformaldehyde in advance. Fixed cells were permeabilized with 0.5% Triton X-100 and blocked with 5% bovine serum albumin (BSA).Then they were incubated for 2 hours with the anti-sera (1:1000 dilution) against the NP of a bat SARS-related CoV as the primary antibody, followed by incubation with Alexa 488-labeled goat anti-rabbit IgG (Abcam, ab150077; 1:500 dilution). The nuclei were stained with DAPI (Sigma-Aldrich, no.D9542). The images were taken by a fluorescence microscopy.

Western blot analysis

For Western blot analysis, proteins were separated by 12% SDS-PAGE and then transferred onto PVDF membranes (Millipore). The membranes were blocked with 5% BSA in TBST (TBS buffer with 0.1% Tween 20) for 1 hour at room temperature. After washed with TBST for three times, the membranes were incubated with the anti-NP sera (1:2000 dilution) overnight at 4°C. After washed with TBST for three times, the membranes were incubated with horseradish peroxidase (HRP)-conjugated Goat Anti-Rabbit IgG (Proteintech, China; 1:10000 dilution). Protein bands were detected by SuperSignal West Pico Chemiluminescent substrate (Pierce).

Clinical investigation

Data collection

Data about demography, clinical manifestations, and laboratory testing results were retrospectively collected by reviewing medical records and entered into standardized database. Medication use during hospitalization including information on antihypertensive drugs (i.e. calcium channel blockers, angiotensin receptor blockers, and diuretics) was also recorded. Serial throat swabs were collected for the testing of HCoV-19 RNA with the use of RT-PCR during the patients’ hospitalization.

Outcome

The primary outcome was case fatality.

Statistics

Continuous variables were summarized as means and standard deviations or as medians and interquartile-range (IQR). Student’s t test or nonparametric test (Mann-Whitney test) was used as appropriate for comparisons of continuous variables between two groups, and ANOVA test or nonparametric test was used as appropriate for comparisons of continuous variables among multiple groups. Categorical variables were summarized as frequencies and proportions, and were analysed by Chi-square test or Fisher’s exact test as appropriate. We used the Kaplan-Meier method and the log-rank test to analyse time-to-event data for treatment effect analysis. We calculated HRs and 95% CI by using Cox regression models. A 2-sided P value of <0.05 was considered to be statistically significant. All statistical analyses were performed using SPSS software, version 19.0.